1. Home
  2. DLPN vs VCNX Comparison

DLPN vs VCNX Comparison

Compare DLPN & VCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DLPN
  • VCNX
  • Stock Information
  • Founded
  • DLPN N/A
  • VCNX 2001
  • Country
  • DLPN United States
  • VCNX United States
  • Employees
  • DLPN N/A
  • VCNX N/A
  • Industry
  • DLPN Other Consumer Services
  • VCNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • DLPN Consumer Discretionary
  • VCNX Health Care
  • Exchange
  • DLPN Nasdaq
  • VCNX Nasdaq
  • Market Cap
  • DLPN 12.9M
  • VCNX 10.5M
  • IPO Year
  • DLPN N/A
  • VCNX N/A
  • Fundamental
  • Price
  • DLPN $1.11
  • VCNX $1.41
  • Analyst Decision
  • DLPN Strong Buy
  • VCNX
  • Analyst Count
  • DLPN 1
  • VCNX 0
  • Target Price
  • DLPN $5.00
  • VCNX N/A
  • AVG Volume (30 Days)
  • DLPN 49.8K
  • VCNX 96.1K
  • Earning Date
  • DLPN 11-14-2024
  • VCNX 11-14-2024
  • Dividend Yield
  • DLPN N/A
  • VCNX N/A
  • EPS Growth
  • DLPN N/A
  • VCNX N/A
  • EPS
  • DLPN N/A
  • VCNX N/A
  • Revenue
  • DLPN $51,389,626.00
  • VCNX $388,000.00
  • Revenue This Year
  • DLPN $21.74
  • VCNX N/A
  • Revenue Next Year
  • DLPN $7.26
  • VCNX N/A
  • P/E Ratio
  • DLPN N/A
  • VCNX N/A
  • Revenue Growth
  • DLPN 21.66
  • VCNX N/A
  • 52 Week Low
  • DLPN $0.95
  • VCNX $1.25
  • 52 Week High
  • DLPN $3.58
  • VCNX $13.02
  • Technical
  • Relative Strength Index (RSI)
  • DLPN 45.36
  • VCNX 27.23
  • Support Level
  • DLPN $1.02
  • VCNX $3.34
  • Resistance Level
  • DLPN $1.20
  • VCNX $4.35
  • Average True Range (ATR)
  • DLPN 0.09
  • VCNX 0.50
  • MACD
  • DLPN -0.00
  • VCNX -0.19
  • Stochastic Oscillator
  • DLPN 26.47
  • VCNX 4.87

About DLPN Dolphin Entertainment Inc.

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

About VCNX Vaccinex Inc.

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Share on Social Networks: